ProMetic Life Sciences Company Profile (TSE:PLI)

Analyst Ratings

Consensus Ratings for ProMetic Life Sciences (TSE:PLI) (?)
Ratings Breakdown: 7 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: C$4.84

Analysts' Ratings History for ProMetic Life Sciences (TSE:PLI)
Show:
DateFirmActionRatingPrice TargetActions
6/15/2016Royal Bank Of CanadaReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016National Bank FinancialReiterated RatingOutperformC$4.90View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/28/2016Paradigm CapitalBoost Price TargetBuyC$2.90 -> C$3.30View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/21/2016CIBCInitiated CoverageSector OutperformerC$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/29/2016Panmure GordonBoost Price TargetBuyC$6.70View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/2/2015ScotiabankBoost Price TargetOutperformC$3.50 -> C$4.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/1/2015Canaccord GenuityBoost Price TargetBuyC$4.25 -> C$4.75View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for ProMetic Life Sciences (TSE:PLI)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for ProMetic Life Sciences (TSE:PLI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.03)($0.03)($0.03)
Q2 20161($0.03)($0.03)($0.03)
Q3 20161($0.03)($0.03)($0.03)
Q4 20161($0.03)($0.03)($0.03)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ProMetic Life Sciences (TSE:PLI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ProMetic Life Sciences (TSE:PLI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/6/2016Bruce PritchardInsiderBuy8,800C$3.19C$28,050.88Tweet This Trade  Share This Trade on StockTwits
4/5/2016Bruce WendelDirectorBuy35,200C$2.45C$86,387.84Tweet This Trade  Share This Trade on StockTwits
1/21/2016Raymond Manuel HakimDirectorBuy10,000C$2.77C$27,700.00Tweet This Trade  Share This Trade on StockTwits
1/20/2016Pierre LaurinDirectorBuy2,000C$2.62C$5,240.00Tweet This Trade  Share This Trade on StockTwits
1/19/2016Gregory WeaverInsiderBuy25,000C$2.78C$69,500.00Tweet This Trade  Share This Trade on StockTwits
1/12/2016Louise M�NardDirectorBuy1,867C$2.94C$5,488.98Tweet This Trade  Share This Trade on StockTwits
12/31/2015Kurt Stefan Victor ClulowDirectorBuy273,800C$3.42C$937,737.62Tweet This Trade  Share This Trade on StockTwits
12/29/2015Kurt Stefan Victor ClulowDirectorBuy232,700C$3.22C$749,875.75Tweet This Trade  Share This Trade on StockTwits
12/21/2015Kurt Stefan Victor ClulowDirectorBuy439,500C$3.16C$1,388,160.75Tweet This Trade  Share This Trade on StockTwits
12/4/2015Gregory WeaverInsiderBuy5,000C$2.14C$10,706.50Tweet This Trade  Share This Trade on StockTwits
12/3/2015Gregory WeaverInsiderBuy5,000C$2.24C$11,184.00Tweet This Trade  Share This Trade on StockTwits
12/3/2015Pierre LaurinDirectorSell259,125C$2.99C$774,913.31Tweet This Trade  Share This Trade on StockTwits
11/17/2015Jonathan BoothInsiderBuy25,000C$2.21C$55,225.00Tweet This Trade  Share This Trade on StockTwits
9/30/2015Kurt Stefan Victor ClulowDirectorBuy50,000C$1.43C$71,500.00Tweet This Trade  Share This Trade on StockTwits
9/29/2015Kurt Stefan Victor ClulowDirectorBuy153,400C$1.42C$217,889.36Tweet This Trade  Share This Trade on StockTwits
9/25/2015Raymond Manuel HakimDirectorBuy15,000C$1.69C$25,399.50Tweet This Trade  Share This Trade on StockTwits
9/15/2015Andrew Trevor BishopDirectorBuy10,000C$1.81C$18,100.00Tweet This Trade  Share This Trade on StockTwits
9/8/2015Simon Geoffrey BestDirectorBuy30,000C$1.95C$58,464.00Tweet This Trade  Share This Trade on StockTwits
8/24/2015Nancy Orr-GaucherDirectorBuy2,800C$1.75C$4,900.00Tweet This Trade  Share This Trade on StockTwits
8/21/2015Pierre LaurinDirectorBuy2,400C$1.83C$4,392.00Tweet This Trade  Share This Trade on StockTwits
7/16/2015Simon Geoffrey BestDirectorBuy60,000C$2.43C$145,782.00Tweet This Trade  Share This Trade on StockTwits
7/15/2015Patrick SartoreInsiderSell122,736C$2.30C$282,722.38Tweet This Trade  Share This Trade on StockTwits
7/15/2015Steven J BurtonDirectorSell49,842C$2.30C$114,811.05Tweet This Trade  Share This Trade on StockTwits
7/2/2015Kurt Stefan Victor ClulowDirectorBuy229,900C$2.32C$533,184.08Tweet This Trade  Share This Trade on StockTwits
6/30/2015Kurt Stefan Victor ClulowDirectorBuy770,100C$2.26C$1,742,736.30Tweet This Trade  Share This Trade on StockTwits
6/29/2015Kurt Stefan Victor ClulowDirectorBuy114,750C$2.10C$240,435.68Tweet This Trade  Share This Trade on StockTwits
6/26/2015Kurt Stefan Victor ClulowDirectorBuy885,250C$2.12C$1,879,208.70Tweet This Trade  Share This Trade on StockTwits
6/16/2015Patrick SartoreInsiderBuy2,300C$2.24C$5,152.00Tweet This Trade  Share This Trade on StockTwits
6/12/2015Patrick SartoreInsiderBuy4,000C$2.28C$9,122.00Tweet This Trade  Share This Trade on StockTwits
6/11/2015Louise M�NardDirectorBuy10,000C$2.35C$23,500.00Tweet This Trade  Share This Trade on StockTwits
6/5/2015Raymond Manuel HakimDirectorBuy50,000C$2.45C$122,495.00Tweet This Trade  Share This Trade on StockTwits
6/4/2015Paul MesburisDirectorSell115,593C$2.40C$277,423.20Tweet This Trade  Share This Trade on StockTwits
5/22/2015Nancy Orr-GaucherDirectorSell9,787C$2.47C$24,173.89Tweet This Trade  Share This Trade on StockTwits
4/9/2015Nancy Orr-GaucherDirectorSell9,657C$2.72C$26,267.04Tweet This Trade  Share This Trade on StockTwits
4/7/2015Bruce PritchardInsiderBuy10,200C$2.74C$27,943.92Tweet This Trade  Share This Trade on StockTwits
2/6/2015John Edward MoranDirectorBuy64,500C$1.51C$97,395.00Tweet This Trade  Share This Trade on StockTwits
1/12/2015Patrick SartoreInsiderSell279,656C$1.87C$523,348.24Tweet This Trade  Share This Trade on StockTwits
1/12/2015Pierre LaurinDirectorSell956,264C$1.87C$1,789,552.45Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for ProMetic Life Sciences (TSE:PLI)
DateHeadline
07/23/16 09:44 AMWere Analysts Bearish ProMetic Life Sciences Inc. (TSE:PLI) This Week? - Consumer Eagle
07/19/16 12:00 PMETF’s with exposure to ProMetic Life Sciences, Inc. : July 19, 2016 -
07/14/16 09:28 AMHow Many ProMetic Life Sciences Inc. (TSE:PLI)'s Analysts Are Bullish? - Press Telegraph
07/11/16 05:49 PMA Reversal for ProMetic Life Sciences Inc. Is Not Near. The Stock Declines Again - Press Telegraph
07/08/16 08:46 AMHereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016 - Research and Markets
07/08/16 07:34 AMProMetic Life Sciences, Inc. breached its 50 day moving average in a Bullish Manner : PLI-CA : July 8, 2016 -
06/14/16 10:41 AMProMetic Life Sciences : plasminogen granted Fast Track designation by the US FDA
06/13/16 05:24 PMProMetic's plasminogen granted Fast Track designation by the US FDA - Edmonton Journal
06/13/16 05:24 PMMood Turns Sour As TSX Logs Losing Skid -- Canadian Commentary - Nasdaq
06/13/16 08:48 AMProMetic's plasminogen granted Fast Track designation by the US FDA - Stockhouse
06/09/16 08:49 AMProMetic Life Sciences to present diabetes drug data - Proactive Investors USA & Canada
05/30/16 12:39 PMProMetic Life Sciences Inc. (PLI) to Post FY2016 Earnings of ($0.08) Per Share, National Bank Financial Forecasts - Let Me Know About This - ProMetic Life Sciences Inc. (PLI) to Post FY2016 Earnings of ($0.08) Per Share, National Bank Financial ForecastsLet Me Know About ThisProMetic Life Sciences logo ProMetic Life Sciences Inc. (TSE:PLI) – Equities researchers at National Bank Financial dropped their FY2016 EPS estimates for ProMetic Life Sciences in a note issued to investors on Wednesday, according to Zacks Investment ...
05/28/16 10:40 AMProMetic Life Sciences Inc. T.PLI - The way I read, they have uped their target price from $4.75 to $4.90. I see their evaluation as being very positive and also a nice consolidated assessment. My only complaint with all the banks and others is when they change their target price they never ...
05/26/16 10:49 AMDoes ProMetic Life Sciences Inc. Have Any Gas After Today's Huge Decline? - Wall Street Hints and News - Does ProMetic Life Sciences Inc. Have Any Gas After Today's Huge Decline?Wall Street Hints and NewsThe stock of ProMetic Life Sciences Inc. (TSE:PLI) is a huge mover today! The stock is down 0.67% or $0.02 after the news, hitting $2.98 per share. About 392,790 shares traded hands. ProMetic Life Sciences Inc. (TSE:PLI) has risen 55.44% since October ...
05/11/16 06:07 AMQ1 2016 ProMetic Life Sciences Inc Earnings Release-Tentative - After Market Close -
04/05/16 10:49 AMProMetic Life Sciences, Inc. :PLI-CA: Earnings Analysis: Q4, 2015 By the Numbers -
04/05/16 09:41 AMProMetic Life Sciences, Inc. :PLI-CA: Earnings Analysis: 2015 By the Numbers -
03/31/16 05:02 PMEdited Transcript of PLI.TO earnings conference call or presentation 31-Mar-16 3:00pm GMT -
03/15/16 12:53 PMProMetic Life Sciences Inc. - 09:48 AM EST - ProMetic Life Sciences Inc. : Announced that it will be initiating a double-blind, placebo-controlled phase 2 clinical trial in patients suffering from scleroderma. ProMetic Life Sciences Inc.
03/11/16 06:40 PMThomvest Asset Management Inc. Reports Prometic Life Sciences Inc. Share Ownership Pursuant To OSC Rule 62-504 - TORONTO, March 11, 2016 /CNW/ - Thomvest Asset Management Inc. (" Thomvest") today filed an initial report of its ownership of common shares and warrants of ProMetic Life Sciences Inc. (the " Corporation") pursuant to OSC Rule 62-504 and corresponding ...
03/03/16 07:35 AMProMetic Life Sciences, Inc. breached its 50 day moving average in a Bullish Manner : PLI-CA : March 3, 2016 -
02/19/16 01:41 PMIs Selling Stock Like ProMetic Life Sciences Inc. After Such Decline Winning Strategy? - Stock Caller - Is Selling Stock Like ProMetic Life Sciences Inc. After Such Decline Winning Strategy?Stock CallerThe stock of ProMetic Life Sciences Inc. (TSE:PLI) is a huge mover today! The stock is down 4.82% or $0.12 after the news, hitting $2.37 per share. About 657,594 shares traded hands. ProMetic Life Sciences Inc. (TSE:PLI) has risen 5.51% since July 14 ...
02/17/16 01:03 PMIs Buying ProMetic Life Sciences Inc. Here a Winning Strategy? The Stock Just Gapped Up - Sonoran Weekly Review - Is Buying ProMetic Life Sciences Inc. Here a Winning Strategy? The Stock Just Gapped UpSonoran Weekly ReviewThe stock of ProMetic Life Sciences Inc. (TSE:PLI) gapped up by $0.01 today and has $3.11 target or 39.00% above today's $2.24 share price. The 5 months technical chart setup indicates low risk for the $1.33B company. The gap was reported on Feb, 16 by ...and more »
02/11/16 12:38 PMProMetic Life Sciences Inc. on Focus After Raising In Today's Session - Sonoran Weekly Review - ProMetic Life Sciences Inc. on Focus After Raising In Today's SessionSonoran Weekly ReviewThe stock of ProMetic Life Sciences Inc. (TSE:PLI) is a huge mover today! The stock increased 1.42% or $0.03 on February 10, hitting $2.14. About 1.07M shares traded hands. ProMetic Life Sciences Inc. (TSE:PLI) has declined 5.38% since July 6, 2015 and ...
02/10/16 12:43 PMProMetric Life Sciences Provides 2016 Milestones Guideline (TSE:PLI) - WallStreet.org - ProMetric Life Sciences Provides 2016 Milestones Guideline (TSE:PLI)WallStreet.orgProMetic Life Sciences Inc. (PLI.TO) today provided its 2016 milestones outlook at the BIO-CEO 2016 conference. With regards to Plasminogen, the Corporation expects to: Further confirm the Plasminogen's safety profile and dose regimen for congenital ...ProMetic Provides 2016 Milestones Outlook at BIO-CEO Conference in New YorkStockhouseall 3 news articles »
02/09/16 12:10 PMProMetic Provides 2016 Milestones Outlook at BIO-CEO Conference in New York - Stockhouse - ProMetic Provides 2016 Milestones Outlook at BIO-CEO Conference in New YorkStockhouseLAVAL, QC, Feb. 9, 2016 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") provided today its 2016 milestones outlook at the BIO-CEO 2016 conference. Pierre Laurin, President and Chief Executive ...and more »
02/08/16 12:11 PMProMetic Life Sciences Inc.'s Stock Is Sell After Today's Huge Decline - Sonoran Weekly Review - ProMetic Life Sciences Inc.'s Stock Is Sell After Today's Huge DeclineSonoran Weekly ReviewThe stock of ProMetic Life Sciences Inc. (TSE:PLI) is a huge mover today! The stock decreased 2.01% or $0.05 on February 5, hitting $2.44. About 1.37M shares traded hands. ProMetic Life Sciences Inc. (TSE:PLI) has risen 3.83% since July 2, 2015 and is ...
01/26/16 11:31 AMProMetic Life Sciences Inc T.PLI - Under the terms of the deal, ProMetic and ProThera each will perform development services in order to advance IAIP to the clinic by 2017. ProMetic has received an initial 11.25 % equity stake in ProThera and such equity position to be increased to 22.5% ...
12/17/15 05:55 AMPROMETIC PROVIDES REVENUE GUIDANCE UPDATE - [at noodls] - • Total 2015 revenues to be $24 million • 2015 product sales to be $21 million, an increase of 94% on 2014 • Q4 sales to reach $14 million, driving total H2 2015 revenues to exceed $19 million in line ...
12/14/15 06:01 AMPROMETIC’S PBI-4050 TO TARGET CYSTIC FIBROSIS AS ITS NEXT ORPHAN INDICATION - [at noodls] - Majority of cystic fibrosis ('CF') patients develop diabetes and liver steatosis PBI-4050 shown to reduce fibrosis in the lungs, pancreas and liver in preclinical models PBI-4050 confirmed to reduce glycated ...
12/14/15 05:30 AMPrometic's PBI-4050 To Target Cystic Fibrosis As Its Next Orphan Indication - [CNW Group] - Prometic's PBI-4050 To Target Cystic Fibrosis As Its Next Orphan Indication
12/11/15 04:44 PMPROMETIC TO DISCLOSE NEW PBI-4050 ORPHAN INDICATION AND HOLD CONFERENCE CALL / WEBCAST - [at noodls] - LAVAL, QUEBEC, CANADA -December 11, 2015 - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ('ProMetic' or the 'Corporation') reported today that it will announce the new orphan indication targeted ...
12/10/15 10:35 AMProMetic Life Sciences, Inc. Earnings Analysis: Q3, 2015 By the Numbers -
12/07/15 05:30 AMProMetic's plasminogen demonstrates rapid therapeutic response in second clinical case - [CNW Group] - ProMetic's plasminogen demonstrates rapid therapeutic response in second clinical case
12/04/15 06:58 AMPROMETIC RENEWS LONG-TERM SUPPLY AGREEMENT WITH GLAXOSMITHKLINE LLC - [at noodls] - LAVAL, QUEBEC, CANADA - December 4, 2015 - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ('ProMetic' or the 'Corporation') announced today that it has renewed its supply agreement with GlaxoSmithKline ...
12/03/15 03:13 AMPROMETIC CONFIRMS PBI-4050’S EFFICACY IN PATIENTS SUFFERING FROM TYPE 2 DIABETES AND METABOLIC SYNDROME - [at noodls] - » Statistically and clinically significant decrease of glycated hemoglobin (HbA1c) at 12 weeks in an open label study » Significant improvement in physical parameters related to metabolic syndrome (waist ...
12/01/15 05:30 AMProMetic confirms PBI-4050's efficacy in patients suffering from type 2 diabetes and metabolic syndrome - [PR Newswire] - LAVAL, QC, Dec. 1, 2015 /CNW Telbec/ - ProMetic Life Sciences Inc. (PLI.TO) (PFSCF) ("ProMetic" or the "Corporation") announced today that it has decided to close patient enrollment in its phase II open label study in patients suffering from type 2 diabetes and metabolic syndrome and will transition to a pivotal placebo-controlled phase II study in patients suffering from type 2 diabetes. This decision is based on the statistically and clinically significant decrease in HbA1C observed in the first 11 patients enrolled that have completed 12 weeks in the study.
11/24/15 06:01 AMPROMETIC TO PRESENT AT THE PIPER JAFFRAY 27TH ANNUAL HEALTHCARE CONFERENCE IN NEW YORK ON TUESDAY DECEMBER 1, 2015 - [at noodls] - ProMetic to provide a clinical program update on its ongoing PBI-4050 metabolic syndrome and type 2 diabetes phase II clinical trial ProMetic to provide a corporate update on other clinical development ...

Social

About ProMetic Life Sciences

ProMetic Life Sciences logoProMetic Life Sciences Inc. (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs. ProMetic is also developing its own small molecule therapeutic products targeting unmet medical needs in the field of fibrosis, autoimmune disease/inflammation and cancer. It has research and development facilities in the United Kingdom, the United States and Canada; manufacturing facilities in the Isle of Man and Canada, and business development activities in the United States, Europe and Asia.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: TSE
  • Symbol: PLI
  • CUSIP:
Key Metrics:
  • Previous Close: $3.03
  • 50 Day Moving Average: $2.96
  • 200 Day Moving Average: $2.93
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.77B
  • Current Year EPS Consensus Estimate: $-0.07 EPS
  • Next Year EPS Consensus Estimate: $N/A EPS
Additional Links:
ProMetic Life Sciences (TSE:PLI) Chart for Tuesday, July, 26, 2016